Eric Christenson, MD, John Hopkins Medicine, Baltimore, MD, reflects on the Phase II trial (NCT03642067) of nivolumab and relatlimab in microsatellite stable (MSS) colorectal cancer (CRC) and their influence on future clinical practices. By understanding which combinations of therapeutics such are the most effective, clinicians can offer a wider range of personalized medicines for patients with MSS or microsatellite instable (MSI) high CRC. Patients with liver-sparing metastatic MSS CRC may also gain more benefit from immunotherapies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
